Topical 5-fluorouracil elicits regressions of BRAF inhibitor-induced cutaneous squamous cell carcinoma.
Seccio Dermatologia, Departament de Medicina, Hospital Universitari Vall d’Hebron, Universitat Autonomade Barcelona, Spain.
Amaya
A
Viros
Robert
R
Hayward
Matthew
M
Martin
Sharona
S
Yashar
Clarissa C
CC
Yu
Berta
B
Sanchez-Laorden
Alfonso
A
Zambon
Dan
D
Niculescu-Duvaz
Caroline
C
Springer
Roger S
RS
Lo
Richard
R
Marais
D015127:9,10-Dimethyl-1,2-benzanthracene / Q000633:toxicity; D000287:Administration, Topical; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002273:Carcinogens / Q000633:toxicity; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D002460:Cell Line; D049109:Cell Proliferation / Q000187:drug effects; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects; D007211:Indoles / Q000009:adverse effects; D008545:Melanoma / Q000188:drug therapy*; D051379:Mice; D010091:Oximes / Q000009:adverse effects; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors*; D012878:Skin Neoplasms / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D013449:Sulfonamides / Q000009:adverse effects; D013755:Tetradecanoylphorbol Acetate / Q000633:toxicity; D000077484:Vemurafenib
D000970:Antineoplastic Agents; D002273:Carcinogens; D007093:Imidazoles; D007211:Indoles; D010091:Oximes; C528407:PLX 4720; D013449:Sulfonamides; D000077484:Vemurafenib; D015127:9,10-Dimethyl-1,2-benzanthracene; C482120:Braf protein, mouse; D048493:Proto-Oncogene Proteins B-raf; D013755:Tetradecanoylphorbol Acetate; C561627:dabrafenib; D005472:Fluorouracil